Associated Papers
Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.
Smith VL et al.
Molecular Therapy. Nucleic Acids, 2026
CHCHD2 links mitochondrial dysfunction and α-synuclein misfolding in Parkinson's disease.
Narendra D et al.
Trends in Neurosciences, 2026
Transcriptional activation by MNRR1 is effected by recruiting p300 and can be induced by minimal peptides.
Purandare N et al.
Mitochondrion, 2026
WES-Based Screening of a Swedish Patient Series with Parkinson's Disease.
Kafantari E et al.
Genes, 2025
CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology.
Liao SC et al.
Science Advances, 2025
The Aggregation Continuum of α-Synuclein and Its Relevance to Brain Aging.
Rana A et al.
Acs Chemical Neuroscience, 2025
Effects of pathological mutations on the CHCHD2 monomer structure: A study by AlphaFold3 linked to the generation of conformational ensembles.
Özmen ZA et al.
Computers in Biology and Medicine, 2025
Amyloid fibril structures link CHCHD10 and CHCHD2 to neurodegeneration.
Lv G et al.
Nature Communications, 2025
Genetics of Parkinson's Disease: From Causes to Treatment.
Westenberger A et al.
Cold Spring Harbor Perspectives in Medicine, 2025
Mitochondrial Dysfunction in Genetic and Non-Genetic Parkinson's Disease.
Lucchesi M et al.
International Journal of Molecular Sciences, 2025
Dysregulation of mitochondrial α-ketoglutarate dehydrogenase leads to elevated lipid peroxidation in CHCHD2-linked Parkinson's disease models.
Gao G et al.
Nature Communications, 2025
Role of the mitochondrial regulatory factor CHCHD2 in neurodegenerative diseases.
Guo X et al.
Frontiers in Neuroscience, 2025
Loss of CHCHD2 Stability Coordinates with C1QBP/CHCHD2/CHCHD10 Complex Impairment to Mediate PD-Linked Mitochondrial Dysfunction.
Ren YL et al.
Molecular Neurobiology, 2024
CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism.
Liao SC et al.
Biorxiv : the Preprint Server for Biology, 2024
CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis.
Ikeda A et al.
Pnas Nexus, 2024
Pathogenesis of Parkinson's disease: from hints from monogenic familial PD to biomarkers.
Hattori N et al.
Journal of Neural Transmission (vienna, Austria : 1996), 2024
Generation of a human iPSC line from a Parkinson's disease patient with a novel CHCHD2 mutation (p.R145Q).
Chen X et al.
Stem Cell Research, 2024
Aberrant CHCHD2-associated mitochondriopathy in Kii ALS/PDC astrocytes.
Leventoux N et al.
Acta Neuropathologica, 2024
Genetic and pharmacologic p32-inhibition rescue CHCHD2-linked Parkinson's disease phenotypes in vivo and in cell models.
Tio M et al.
Journal of Biomedical Science, 2024
CHCHD2 Thr61Ile mutation impairs F1F0-ATPase assembly in in vitro and in vivo models of Parkinson's disease.
Chen X et al.
Neural Regeneration Research, 2024
Peripheral cutaneous synucleinopathy characteristics in genetic Parkinson's disease.
Yuan Y et al.
Frontiers in Neurology, 2024
CHCHD10 mutations induce tissue-specific mitochondrial DNA deletions with a distinct signature.
Shammas MK et al.
Human Molecular Genetics, 2023
Involvement of Mitochondria in Parkinson's Disease.
Choong CJ et al.
International Journal of Molecular Sciences, 2023
Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.
Torii S et al.
Embo Molecular Medicine, 2023